How to diagnose and manage antiphospholipid syndrome

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):606-613. doi: 10.1182/hematology.2023000493.

Abstract

Antiphospholipid antibodies (aPL) are autoimmune antibodies directed toward phospholipids or phospholipid-protein complexes, particularly those containing β2-glycoprotein I (β2GPI). Persistently positive aPL accompanied by arterial or venous thrombosis, or recurrent pregnancy loss, constitutes the antiphospholipid syndrome (APS). Several types of aPL with different specificities have been defined and may be detected in the clinical lab, including lupus anticoagulants (detected using clotting assays) and anticardiolipin, anti-β2GPI and anti-prothrombin/phosphatidylserine antibodies (detected by ELISA); each of the last 3 aPL may be either IgG, IgM, or IgA, though IgA antibodies are not included in criteria for APS. Due to the relative rarity of APS and the heterogeneity of aPL, thrombosis risk stratification is challenging, and randomized clinical trials for thrombosis treatment and prevention have been limited. This lack of high-quality data has made the clinical management of APS difficult, and existing guidelines are few and could not possibly cover many of the scenarios encountered in managing patients with APS. In this review, we present 3 patients with aPL and/or APS who highlight treatment dilemmas, and we discuss background information that may help guide clinical judgment in developing individualized treatment plans for patients with these enigmatic antibodies.

Publication types

  • Review

MeSH terms

  • Antibodies, Antiphospholipid
  • Antiphospholipid Syndrome* / diagnosis
  • Antiphospholipid Syndrome* / therapy
  • Female
  • Humans
  • Immunoglobulin A
  • Lupus Coagulation Inhibitor
  • Pregnancy
  • Thrombosis* / diagnosis
  • Thrombosis* / therapy
  • beta 2-Glycoprotein I

Substances

  • Antibodies, Antiphospholipid
  • Lupus Coagulation Inhibitor
  • beta 2-Glycoprotein I
  • Immunoglobulin A